Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - Eli Lilly’s profit doubled in the fourth ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

In all, 44% of those taking dapagliflozin along with the other measures saw their diabetes go into remission -- defined as ...

New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...